DDInter1635 DDInter1676
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Salmeterol {u} may lead to a major life threatening interaction when taken with {v} Labetalol
Salmeterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salmeterol {u} (Compound) resembles {v} (Compound) Hexoprenaline
Salmeterol {u} (Compound) treats {v} (Disease) asthma
Salmeterol {u} (Compound) binds {v} (Gene) ADRB2
Salmeterol {u} (Compound) upregulates {v} (Gene) EDEM1
Salmeterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Salmeterol {u} (Compound) downregulates {v} (Gene) CDC20
Salmeterol {u} (Compound) causes {v} (Side Effect) Chronic obstructive pulmonary disease
Salmeterol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hydrocortisone
Salmeterol may lead to a major life threatening interaction when taken with Labetalol
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Salmeterol (Compound) resembles Hexoprenaline (Compound)
Salmeterol (Compound) treats asthma (Disease)
Salmeterol (Compound) binds ADRB2 (Gene)
Salmeterol (Compound) upregulates EDEM1 (Gene)
Salmeterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Salmeterol (Compound) downregulates CDC20 (Gene)
Salmeterol (Compound) causes Chronic obstructive pulmonary disease (Side Effect)
Salmeterol may cause a minor interaction that can limit clinical effects when taken with Hydrocortisone